463 related articles for article (PubMed ID: 35265202)
1. Platinum-based drugs for cancer therapy and anti-tumor strategies.
Zhang C; Xu C; Gao X; Yao Q
Theranostics; 2022; 12(5):2115-2132. PubMed ID: 35265202
[TBL] [Abstract][Full Text] [Related]
2. Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review.
Szefler B; Czeleń P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675064
[TBL] [Abstract][Full Text] [Related]
3. Advancements in the Use of Platinum Complexes as Anticancer Agents.
Sharma R; Singh VJ; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):821-835. PubMed ID: 34353272
[TBL] [Abstract][Full Text] [Related]
4. Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer.
Tanabe S; Boonstra E; Hong T; Quader S; Ono R; Cabral H; Aoyagi K; Yokozaki H; Perkins EJ; Sasaki H
Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003016
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
6. The Power of Kinetic Inertness in Improving Platinum Anticancer Therapy by Circumventing Resistance and Ameliorating Nephrotoxicity.
Panda TR; M M; Vaidya SP; Chhatar S; Sinha S; Mehrotra M; Chakraborty S; Gadre S; Duari P; Ray P; Patra M
Angew Chem Int Ed Engl; 2023 Sep; 62(38):e202303958. PubMed ID: 37314332
[TBL] [Abstract][Full Text] [Related]
7. New strategies against prostate cancer--Pt(II)-based chemotherapy.
Matos CS; de Carvalho AL; Lopes RP; Marques MP
Curr Med Chem; 2012; 19(27):4678-87. PubMed ID: 22856665
[TBL] [Abstract][Full Text] [Related]
8. Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs.
Román DA; Pizarro I; Rivera L; Torres C; Avila J; Cortés P; Gill M
BMC Res Notes; 2012 Apr; 5():207. PubMed ID: 22546077
[TBL] [Abstract][Full Text] [Related]
9. Recent Progresses in Conjugation with Bioactive Ligands to Improve the Anticancer Activity of Platinum Compounds.
Zuccolo M; Arrighetti N; Perego P; Colombo D
Curr Med Chem; 2022; 29(15):2566-2601. PubMed ID: 34365939
[TBL] [Abstract][Full Text] [Related]
10. Platinum compounds in children with cancer: toxicity and clinical management.
Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
Stojanovska V; McQuade R; Rybalka E; Nurgali K
Curr Med Chem; 2017; 24(15):1520-1536. PubMed ID: 28079002
[TBL] [Abstract][Full Text] [Related]
12. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
13. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.
Gersten BK; Fitzgerald TS; Fernandez KA; Cunningham LL
J Assoc Res Otolaryngol; 2020 Aug; 21(4):303-321. PubMed ID: 32583132
[TBL] [Abstract][Full Text] [Related]
14. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?
Bowden NA
Cancer Lett; 2014 May; 346(2):163-71. PubMed ID: 24462818
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.
Ho GY; Woodward N; Coward JI
Crit Rev Oncol Hematol; 2016 Jun; 102():37-46. PubMed ID: 27105947
[TBL] [Abstract][Full Text] [Related]
16. H-Dot Mediated Nanotherapeutics Mitigate Systemic Toxicity of Platinum-Based Anticancer Drugs.
Yamashita A; Park SH; Zeng L; Stiles WR; Ahn S; Bao K; Kim J; Kang H; Choi HS
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895146
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
Stordal B; Pavlakis N; Davey R
Cancer Treat Rev; 2007 Jun; 33(4):347-57. PubMed ID: 17383100
[TBL] [Abstract][Full Text] [Related]
18. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
19. Clinical Evidence of Interaction between Nutraceutical Supplementation and Platinum-based Chemotherapy.
Cocetta V; Tinazzi M; Giacomini I; Rosato B; Ragazzi E; Berretta M; Montopoli M
Curr Med Chem; 2023; 30(19):2141-2164. PubMed ID: 35638272
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
